NCT02142205 - Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

BIOLOGICAL

BG00002

IV Infusion

Trial Locations (11)

Research Site, Belgorod

Research Site, Kaluga

Research Site, Kazan'

Research Site, Krasnodar

Research Site, Kursk

Research Site, Moscow

Research Site, Nizhny Novgorod

Research Site, Perm

Research Site, Rostov-on-Don

Research Site, Saint Petersburg

Research Site, Smolensk